Combination of organic compounds

Details for Australian Patent Application No. 2003240261 (hide)

Owner Novartis AG

Inventors Shetty, Suraj Shivappa; Webb, Randy Lee

Agent Davies Collison Cave

Pub. Number AU-B-2003240261

PCT Number PCT/EP03/05180

PCT Pub. Number WO2003/097045

Priority 60/381,547 17.05.02 US

Filing date 16 May 2003

Wipo publication date 2 December 2003

Acceptance publication date 28 June 2007

International Classifications

C07D 285/28 (2006.01) Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups

A61K 31/19 (2006.01)

A61K 31/196 (2006.01)

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 31/4184 (2006.01)

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/4422 (2006.01) - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

A61K 31/549 (2006.01) - having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 5/42 (2006.01) Drugs for disorders of the endocrine system

A61P 7/10 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/04 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/06 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/12 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/14 (2006.01) Drugs for disorders of the cardiovascular system

A61P 13/12 (2006.01) Drugs for disorders of the urinary system

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 25/06 (2006.01) Drugs for disorders of the nervous system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 27/06 (2006.01) Drugs for disorders of the senses

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

11 September 2003 Complete Application Filed

  Priority application(s): 60/381,547 17.05.02 US

29 January 2004 Application Open to Public Inspection

  Published as AU-B-2003240261

28 June 2007 Application Accepted

  Published as AU-B-2003240261

25 October 2007 Standard Patent Sealed

28 October 2010 Extension of Term of Standard Patents

  Novartis AG The earliest first regulatory approval date provided by the patentee 09 Apr 2010 For the goods EXFORGE HCT

23 December 2010 Extension of Term of Standard Patents

  Novartis AG The earliest first regulatory approval date provided by the patentee 09 Apr 2010 For the goods EXFORGE HCT Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000

14 July 2011 Extension granted

  Novartis AG The earliest first regulatory approval date provided by the patentee 09 Apr 2010 For the goods EXFORGE HCT Extension of Term of patent pursuant to Section 77 expires on 09 Apr 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003240262-POLYMORPHISM OF SOATI USEFUL FOR IDENTIFYING RISK OF DEVELOPING ALZHEIMER'S DISEASE

2003240260-Method and reagent system having a non-regenerative enzyme-coenzyme complex